26117-28-2

Basic information

• Product Name: N-acetyl-D-cysteine
• Synonyms: N-acetyl-D-cysteine;Cysteine, N-acetyl-, D- (8CI);D-Cysteine, N-acetyl-;D-N-Acetylcysteine;N-Acetyl-(S)-cysteine;(S)-2-(Acetylamino)-3-mercaptopropanoic acid;(S)-2-Acetylamino-3-mercaptopropionic acid;Einecs 247-470-5
• CAS NO: 26117-28-2
• Molecular Formula: C₅H₉NO₃S
• Molecular Weight: 163.19486
• EINECS: 247-470-5
• Mol File: 26117-28-2.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 407.7°C at 760 mmHg
• Flash Point: 200.4°C
• Appearance: /
• Density: 1.294g/cm³
• Vapor Pressure: 8.68E-08mmHg at 25°C
• Refractive Index: 1.518
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: DMSO (Slightly), Methanol (Slightly), Water (Slightly)
• PKA: 3.25±0.10(Predicted)
• Stability: Air Sensitive, Hygroscopic
• CAS DataBase Reference: N-acetyl-D-cysteine(CAS DataBase Reference)
• NIST Chemistry Reference: N-acetyl-D-cysteine(26117-28-2)
• EPA Substance Registry System: N-acetyl-D-cysteine(26117-28-2)

Safety Data

• Hazardous Substances Data: 26117-28-2(Hazardous Substances Data)

Usage

Description

N-Acetyl-D-cysteine is an isomer of N-Acetyl Cysteine, a naturally occurring amino acid derivative that possesses antioxidant and radioprotective properties. It plays a crucial role in maintaining cellular redox balance and protecting cells from oxidative stress and damage caused by high-dose irradiation.

Uses

Used in Pharmaceutical Industry:
N-Acetyl-D-cysteine is used as a radioprotectant for protecting cells and tissues from oxidative damage caused by high-dose irradiation. Its antioxidant properties help neutralize reactive oxygen species and reduce the harmful effects of radiation on the body.
Used in Antioxidant Applications:
N-Acetyl-D-cysteine is used as an antioxidant to support the body's natural defense mechanisms against oxidative stress. It helps maintain cellular redox balance and protect cells from damage caused by reactive oxygen species, thus promoting overall health and well-being.
Used in Research and Development:
N-Acetyl-D-cysteine is utilized in research and development for studying the effects of oxidative stress and radiation on cellular processes. Its radioprotective properties make it a valuable tool for understanding the mechanisms of radiation-induced damage and developing potential therapeutic strategies to mitigate these effects.

InChI:InChI=1/C5H9NO3S/c1-3(7)6-4(2-10)5(8)9/h4,10H,2H2,1H3,(H,6,7)(H,8,9)/t4-/m1/s1

Upstream product

• 19538-71-7 N-acetyl-S-benzyl-D,L-cysteine 
• 60-24-2 2-hydroxyethanethiol 
• 118456-64-7 ethyl N-acetyl-S-benzyl-D,L-cysteinate 
• 7218-04-4 N-Acetylcysteine 
• 921-01-7 D-cysteine 

Downstream Products

• 7652-46-2 2-acetylamino-3-mercapto-propionic acid methyl ester 
• 15139-21-6 5-thio-2-nitrobenzoic acid 
• 103-90-2 4-acetaminophenol 
• 60603-13-6 2-acetamido-3-(5′-acetamido-2′-hydroxyphenylthio) propanoic acid 
• 75785-50-1 N-acetyl-S-(2,3-dihydroxy-4-heptadecylphenyl)cysteine 
• 75-66-1 2-methylpropan-2-thiol 
• 60-24-2 2-hydroxyethanethiol 
• 75-08-1 ethanethiol 
• 75-33-2 2-propanethiol 
• 2935-90-2 Methyl 3-mercaptopropionate 
• 6258-66-8 (4-chlorophenyl)methanethiol 
• 52-90-4 L-Cysteine 
• 26117-28-2 (S)-N-acetylcysteine 
• 921-01-7 rac-cysteine 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR THE TREATMENT OF COUGH

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing cough may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of acute respiratory tract infections, asthma, gout, fibromyalgia, facilitating conception, promotes secondary mucosal secretions in the respiratory system, muscle relaxant, allergy, asthma, chronic obstructive pulmonary disorders, spasms, respiratory and neurological diseases.

Combination Therapies for Treating Metabolic Disorders

This invention is directed to pharmaceutical combinations comprising an antioxidant agent, an anti-inflammatory agent, and optionally at least one other anti-diabetic agent useful for treating metabolic disorders. This invention also encompasses pharmaceutically acceptable compositions comprising an antioxidant agent, an anti-inflammatory agent, optionally at least one other anti-diabetic agent, and at least one pharmaceutically acceptable carrier. The combinations and compositions of this invention are useful as methods for treating metabolic disorders including diabetes, particularly Type I and Type II diabetes, as well as diseases and disorders associated with diabetes, including but not limited to atherosclerosis, cardiovascular disease, inflammatory disorders, nephropathy, neuropathy, retinopathy, β-cell dysfunction, dyslipidemia, LADA, metabolic syndrome, hyperglycemia, insulin resistance, and/or chronic obstructive pulmonary disease in a mammal, particularly a diabetic mammal, and specifically a human patient. This invention is particularly directed to pharmaceutical compositions comprising an lipoic acid, one or more anti-inflammatories selected from the group consisting of diflunisal, diclofenac, dexibuprofen, dexketoprofen, naproxen, and salicylate, and optionally one or more pharmaceutically acceptable carriers. The compositions of this invention are useful as methods for treating metabolic disorders including type II diabetes, insulin resistance, beta-cell dysfunction, and hyperglycemia in a patient, particularly a diabetic patient.